Christian W Keller
Overview
Explore the profile of Christian W Keller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1920
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stascheit F, de Sousa C, Aigner A, Behrens M, Keller C, Klotz L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Nov;
12(1):e200331.
PMID: 39602677
Background And Objectives: Biologics that target pathogenic antibodies (Abs) and their effector functions such as the complement inhibitor ravulizumab and the neonatal Fc receptor agonist efgartigimod have recently been approved...
2.
Keller C, Mundt S, Segal B
Front Immunol
. 2024 Aug;
15:1459138.
PMID: 39086488
No abstract available.
3.
Chuquisana O, Stascheit F, Keller C, Pucic-Bakovic M, Patenaude A, Lauc G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Mar;
11(3):e200220.
PMID: 38507656
Background And Objectives: Antibodies (Abs) specific for the low-density lipoprotein receptor-related protein 4 (LRP4) occur in up to 5% of patients with myasthenia gravis (MG). The objective of this study...
4.
Keller C, Adamopoulos I, Lunemann J
J Autoimmun
. 2023 Mar;
136:103030.
PMID: 37001435
Autophagy comprises a growing range of cellular pathways, which occupy central roles in response to energy deprivation, organelle turnover and proteostasis. Over the years, autophagy has been increasingly linked to...
5.
Stascheit F, Chuquisana O, Keller C, Ambrose P, Hoffmann S, Gross C, et al.
Eur J Neurol
. 2023 Feb;
30(5):1409-1416.
PMID: 36752022
Background And Purpose: Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody (AChR-Ab ) generalized myasthenia gravis (MG). That clearly implicates antibody-mediated complement activation...
6.
Spatola M, Chuquisana O, Jung W, Lopez J, Wendel E, Ramanathan S, et al.
Cell Rep Med
. 2023 Jan;
4(2):100913.
PMID: 36669487
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs...
7.
Keller C, Chuquisana O, Derdelinckx J, Gross C, Berger K, Robinson J, et al.
Ann Neurol
. 2022 Sep;
92(6):1046-1051.
PMID: 36094152
Myasthenia gravis (MG) is an autoimmune disease in which pathogenic immunoglobulin G antibodies bind to acetylcholine receptors (or to functionally related molecules at the neuromuscular junction). B cell expression of...
8.
Chuquisana O, Strippel C, Troscher A, Baumgartner T, Racz A, Keller C, et al.
Acta Neuropathol
. 2022 Jun;
144(2):381-383.
PMID: 35697881
No abstract available.
9.
Keller C, Lopez J, Wendel E, Ramanathan S, Gross C, Klotz L, et al.
Ann Neurol
. 2021 Dec;
91(2):300-301.
PMID: 34862658
No abstract available.
10.
Keller C, Lopez J, Wendel E, Ramanathan S, Gross C, Klotz L, et al.
Ann Neurol
. 2021 Sep;
90(6):976-982.
PMID: 34569094
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated diseases (MOGADs) account for a substantial proportion of pediatric and adult patients who present with acquired demyelinating disorders. Its pathogenesis and optimal therapy are incompletely...